Knopp Biosciences to Present Clinical Data for Dexpramipexole at 11th Biennial Symposium of the International Eosinophil Society
Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today announced poster and oral presentations on data for its small molecule immunological therapy, dexpramipexole, at the 11th Biennial Symposium of the International Eosinophil Society to be held in Portland, Oregon, on July 9-13.
Poster Presentation Title: Dexpramipexole Responsiveness is Increased in Eosinophilic Patients
Date & Time: July 10, 5:00 pm PDT
Oral Presentation Title:
Developing Dexpramipexole for the Treatment of Eosinophilic Disorders
Speaker: Calman Prussin, M.D., Vice President, Clinical and Translational Medicine, Knopp Biosciences
Date & Time: July 13, 8:30 am PDT
Dr. Prussin will present an analysis of the eosinophil-lowering effects of dexpramipexole seen in a Phase 3 randomized, double-blind, placebo-controlled study of dexpramipexole in amyotrophic lateral sclerosis (ALS) conducted at 81 centers in 11 countries. The study included 419 dexpramipexole-treated patients. The analysis showed that the magnitude of eosinophil lowering by dexpramipexole increased in a stepwise manner in subjects with greater baseline eosinophil counts, with the greatest effect seen in subjects with baseline eosinophilia.
The findings help explain the greater eosinophil lowering seen in previous trials of dexpramipexole in eosinophil-associated diseases relative to ALS. These results indicate that dexpramipexole is most effective in a milieu of greater pro-eosinophilia signaling, further suggesting that dexpramipexole acts on a pathway driven by inflammatory signaling molecules such as IL-5. Irrespective of baseline eosinophil count, absolute eosinophil count was lowered to the 0.02-0.03x109/L range, suggesting that dexpramipexole may have minimal effects on non-IL-5-driven homeostatic eosinophil populations.
In his oral presentation, Dr. Prussin will present an overview of data on the eosinophil-lowering effects of dexpramipexole observed in clinical studies for hypereosinophilic syndrome (HES) and chronic rhinosinusitis with nasal polyps (CRSwNP).
Eosinophils are white-blood cells that play a central role in a number debilitating conditions beyond ALS, including asthma, HES and other inflammatory diseases. Knopp has reported Phase 2 clinical trial results in HES and CRSwNP and is initiating a Phase 2 trial in severe eosinophilic asthma.
ABOUT KNOPP BIOSCIENCES LLC
Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need. Knopp’s clinical-stage small molecule, dexpramipexole, is entering Phase 2 clinical trials in severe eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small molecule treatments for neonatal epileptic encephalopathy, other rare epilepsies, and neuropathic pain. Please visit www.knoppbio.com.
This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190709005223/en/
Contact information
Media inquiries:
James Heins
james.heins@icrinc.com
203-682-8251
Surabhi Verma
surabhi.verma@icrinc.com
646-677-1825
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Access Advance Announces HEVC Advance and VVC Advance Pricing through 203022.7.2025 03:00:00 EEST | Press release
Access Advance LLC (“Advance”) today announced the results of several significant decisions by the Licensors in both the HEVC Advance and VVC Advance Patent Pools. Both patent pools opted to maintain their current royalty rates and caps for Licensees who sign before December 31, 2025, and to extend an incentive that aligns the royalty caps for Advance’s Multi-Codec Bridging Agreement (“MCBA”) and the VVC Advance Patent Pool for Licensees who sign the MCBA during the same period. The result is that Licensees who join the HEVC Advance program, gaining access to more than 27,000 patents, on or before December 31, 2025, can lock in current rates and caps through 2030. This protection applies both to ongoing royalty obligations and calculation of royalties due for past sales. Additionally, both current and new HEVC Advance Licensees who join the VVC Advance Patent Pool and execute the MCBA by December 31, 2025, will enjoy MCBA royalty caps that match the royalty caps for the VVC Advance pro
MayMaan Launches Engine Integration Program to Accelerate Clean Combustion Deployment and Market Adoption21.7.2025 20:34:00 EEST | Press release
MayMaan, a scale-up innovator, transforming combustion technology, is announcing a robust and scalable partnership model to support the transition to more efficient power systems across global industries whilst cutting harmful emissions such as NOx and SOx to levels that are practically immeasurable. At the heart of MayMaan’s offering is its proprietary AquaStroke® technology, which runs on a revolutionary 70% water and 30% ethanol fuel blend. This patented system delivers high torque and reliability while dramatically reducing emissions—offering a compelling alternative to diesel engines and electrification overhauls. “Our technology is more than a breakthrough—it’s a platform designed to help others succeed,” said Doron Shmueli, Founder and CEO at MayMaan. “From manufacturers to distributors, we provide a full solution—ready to integrate, easy to scale, and built for the energy demands of tomorrow.” Tailored Solutions for Industry Leaders MayMaan’s clean combustion platform is now av
Armis Named a Leader in Unified Vulnerability Management Solutions, Q3 2025 Evaluation21.7.2025 18:25:00 EEST | Press release
Armis, the cyber exposure management & security company, today announced that it has been named a Leader in The Forrester Wave™: Unified Vulnerability Management Solutions, Q3 2025. In this Forrester Wave™, Armis is ranked a Leader and achieved the highest score in the Current Offering category. According to the report, “Armis’ strategy is grounded in proactive security principles… Armis is an excellent fit for either beginner organizations starting their proactive security journey or mature organizations that need leading vulnerability response capabilities.” “I believe Armis stood out as a Leader because Armis CentrixTM is different – it’s a platform built to help organizations reduce cyber risk, not just report on it,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “We are redefining what security should look like in a connected world, helping organizations move from passive defense to proactive control so that they can take action before there’s any impact on their environment.
DevvStream Completes $10M Initial Funding to Launch $300M Asset-Backed Digital Infrastructure and Sustainability Strategy21.7.2025 18:00:00 EEST | Press release
DevvStream Corp. (Nasdaq: DEVS) (“DevvStream” or the “Company”), a leading carbon management firm specializing in the development, investment, and sale of environmental assets, today announced that it has entered into a securities purchase agreement for the issuance of up to (US)$300 million in senior secured convertible notes (“Senior Notes”), advancing its strategic initiative to build a blockchain-based treasury and launch a tokenization platform for sustainability-linked infrastructure. The securities purchase agreement provides for the issuance of up to (US)$300 million in Senior Notes with Helena Partners, which issuances will be funded in multiple tranches. An initial funding of (US)$10 million was completed on July 18, 2025. Key Highlights: Under the agreement, DevvStream will allocate 75% of the net proceeds (70% of the initial tranche) toward the purchase of liquid digital assets that offer 24/7 liquidity, serve as non-correlated stores of value, and may be used as collateral
McCauley Propeller Systems High-Performance C780 Propeller Now Factory Standard for New Beechcraft King Air 360 Customers21.7.2025 16:00:00 EEST | Press release
McCauley Propeller Systems, a division of Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced its C780 propeller, which had previously been optional for factory installation, is now standard for all new commercial customers of the Beechcraft King Air 360. The first King Air 360 equipped with the propeller recently rolled out of production at Textron Aviation’s factory in Wichita, Kansas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250720080635/en/ McCauley Propeller Systems high-performance C780 propeller now factory standard for new Beechcraft King Air 360 customers (Photo Credit: McCauley Propeller Systems) "As a leading full-line propeller manufacturer, being featured on the factory line of the legendary Beechcraft King Air 360 underscores our commitment to excellence," said Jason Hull, vice president and general manager, McCauley Propeller Systems. “The C780 offers a sophisticated and durable de
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom